Market Overview

Medtronic Completes Enrollment in Landmark Study of IN.PACT Drug-Eluting Balloon in Peripheral Artery Disease

Share:
Related MDT
UPDATE: Medtronic plc: FDA Approves the VenaSeal Closure System for Treatment of Clinically Symptomatic Venous Reflux
3 Companies That Could Be Negatively Impacted By Johnson & Johnson Sale Of Cordis
Medtronic's VenaSeal Wins FDA Nod for Vericose Veins Cure - Analyst Blog (Zacks)

Committed to researching treatments for peripheral artery disease, Medtronic, Inc. (NYSE: MDT) today announced that patient enrollment in a landmark study of its IN.PACT Amphirion drug-eluting balloon is complete, with initial results expected in 2013.

The largest randomized controlled trial of its kind, IN.PACT DEEP is designed to assess the safety and efficacy of the IN.PACT Amphirion drug-eluting balloon as a treatment for one of the most severe forms of peripheral artery disease -- critical limb ischemia that occurs below the knee.

Posted-In: News FDA

 

Related Articles (MDT)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Our Experts vs. S&P 500Powered by Benzinga
Marketfy Products Return S&P 500
Morning Profit Maker 42.72% 6.69%
The Option Prophet 91.14% 6.69%
SecretCaps 26.55% 6.69%
Short-Term Trend Trading 11.89% 6.69%
View the highest rated products→